Analysis in progress
Initialising…
0%
complete
This report is still being assembled — sections appear as each stage finishes. It isn't final yet.
KMT2A
Final classification
VUS
KMT2A c.2040G>T · p.Ser680=
KMT2A ·synonymous

PM2 (Supporting): total allele frequency 0.001% in gnomAD, well below the 0.1% threshold, with no homozygotes.

Gene
KMT2A
Transcript
NM_005933.3
HGVS · transcript:coding
NM_005933.3:c.2040G>T
Consequence
synonymous
exon 3
GRCh38
chr11:118473199 G>T
GRCh37
chr11:118343914 G>T
Basis Variant of Uncertain Significance: one supporting (PM2) plus one supporting (BP7) meets no benign or pathogenic threshold under the generic ACMG/AMP 2015 rules.
Variant of Uncertain Significance: one supporting (PM2) plus one supporting (BP7) meets no benign or pathogenic threshold under the generic ACMG/AMP 2015 rules.
Classification rationale
PM2 BP7 VUS
KMT2A c.2040G>T synonymous · exon 3

PM2 (Supporting): total allele frequency 0.001% in gnomAD, well below the 0.1% threshold, with no homozygotes. BP7 (Supporting): synonymous p.Ser680= deep in exon 3, with no predicted splice impact (SpliceAI max delta 0.006). VUS: the single supporting plus single supporting combination (PM2 + BP7) meets no benign, likely benign, likely pathogenic, or pathogenic rule under generic ACMG/AMP 2015.

PM2 + BP7 VUS
Gene diagram · NM_005933.3 · variants mapped to exon structure
KMT2A NM_005933.3
Fetching transcript structure from UCSC…
Applied criteria · 2 applied · 17 assessed
Applied · 2
Strength Supporting Moderate Strong Very strong
PM2 supporting Pathogenic
Met (supporting): gnomAD total allele frequency is 0.001%, far below the 0.1% PM2 threshold, with no homozygotes.
Local non-VCEP PM2 threshold: allele frequency <0.1% (absent or extremely low frequency in controls, per ACMG/AMP 2015 PM2 definition, PMID 25741868).gnomAD v2.1 (gnomad_v2): total AF 1.06503e-05 (0.00107%, 3/281,682 alleles), 0 homozygotes; East Asian max subpopulation AF 0.01505%; grpmax FAF 0.00022756 (0.023%) — all below 0.1%.gnomAD v4.1 (gnomad_v4): total AF 1.11571e-05 (0.00112%, 18/1,613,328 alleles), 0 homozygotes; East Asian max subpopulation AF 0.02228%; grpmax FAF 0.00012016 (0.012%) — all below 0.1%.
BP7 supporting Benign
Met (supporting): synonymous p.Ser680= deep in exon 3 with SpliceAI max delta 0.006, well below the 0.2 splice-altering threshold.
Variant normalization confirms NM_005933.3:c.2040G>T is synonymous, NP_005924.2:p.(Ser680=), in exon 3 of the KMT2A transcript.SpliceAI (Jaganathan et al. 2019, PMID 30661751; spliceailookup.broadinstitute.org) predicts no splice impact for NM_005933.3:c.2040G>T: max delta 0.006 (DS_AG=0.001, DS_AL=0.0, DS_DG=0.0, DS_DL=0.006), well below the 0.2 splice-altering threshold; no impact on the splice consensus sequence and no creation of an alternate splice site predicted.Variant position c.2040 lies ~1.5 kb from the 5' end and ~1.1 kb from the 3' end of exon 3 (exon span c.503-3156), i.e., not within or near any canonical splice consensus sequence.
Assessed · not applied
Pathogenic
PS2 Not assessed: no parental genotyping or trio data were available to confirm a de novo occurrence.
PS3 Not assessed: no functional studies of this variant were available to evaluate a deleterious effect.
PS4 Not assessed: no case-control or affected-versus-control enrichment data were available.
PM6 Not assessed: no proband or parental genotyping data were available to evaluate assumed de novo status.
PP1 Not assessed: no family or segregation data were available to evaluate co-segregation with disease.
PP3 Not met: SpliceAI max delta 0.006 is far below the 0.2 splice-altering threshold, and missense predictors do not apply.
PP4 Not assessed: no proband-level phenotype data were available to evaluate phenotype specificity.
PP5 Not met: no ClinVar expert-panel classification exists for this exact variant; only a single-submitter Likely benign assertion.
Benign
BA1 Not met: allele frequency 0.001% is orders of magnitude below the 1% BA1 threshold.
BS1 Not met: observed allele frequency 0.001% does not exceed the 0.3% BS1 threshold.
BS2 Not met: gnomAD carriers are not phenotype-screened for this early-onset disorder, so unaffected adult status is not demonstrated.
BS3 Not assessed: no well-established functional studies showing no damaging effect were available.
BS4 Not assessed: no family segregation data were available to demonstrate lack of segregation.
BP2 Not met: no observation in trans or cis with a pathogenic variant is documented in any source.
BP4 Not met: no independent BP4 prediction exists beyond the SpliceAI result already applied under BP7.
BP5 Not assessed: no affected carrier is reported in whom an alternate molecular basis could be documented.
BP6 Not met: no ClinVar expert-panel benign assertion exists; a single-submitter Likely benign label does not trigger BP6.
N/A · 9 PVS1 · PS1 · PM1 · PM3 · PM4 · PM5 · PP2 · BP1 · BP3
Research & evidence
Population frequency
gnomAD v4.1 screenshot
gnomAD v4.1
gnomAD v2.1 screenshot
gnomAD v2.1
v4.1
This variant is present in gnomAD v4.1 (AF= 1.11571e-05; MAF= 0.00112%, 18/1613328 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.000222777; MAF= 0.02228%, 10/44888 alleles, homozygotes = 0); grpmax FAF= 0.00012016.
v2.1
This variant is present in gnomAD v2.1 (AF= 1.06503e-05; MAF= 0.00107%, 3/281682 alleles, homozygotes = 0) and has highest observed frequency in the East Asian population (AF= 0.000150482; MAF= 0.01505%, 3/19936 alleles, homozygotes = 0); grpmax FAF= 0.00022756.
🇨🇦 CA
Not available in gnomAD-Canada v1.0.
Allele frequency by ancestry
three datasets · side by side
gnomAD v4.1
0.0011% · 18 / 1,613,328
0 hom · FAF 0.012%
East Asian
10 / 44,888
0.022%
Remaining individuals
8 / 62,440
0.013%
+ 8 not observed (Admixed American, European (Finnish), Amish, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American, European (non-Finnish))
gnomAD v2.1
0.0011% · 3 / 281,682
0 hom · FAF 0.023%
East Asian
3 / 19,936
0.015%
+ 7 not observed (African/African American, Admixed American, Ashkenazi Jewish, European (Finnish), European (non-Finnish), Remaining individuals, South Asian)
gnomAD Canada 🇨🇦
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar screenshot
ClinVar
This variant has been reported in ClinVar as Likely benign (1 clinical laboratory). (ClinVarID = 1576960)
SpliceAI screenshot
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01).
Functional / OncoKB screenshot
Functional Unknown Oncogenic Effect
OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: Unknown Oncogenic Effect.
OncoKB ↗
COSMIC screenshot
COSMIC
Cancer hotspots screenshot
Cancer hotspots
Somatic evidence Not in COSMIC / hotspots
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).
Hotspots
This variant does not lie in a statistically significant hotspot.
Sources & reference links
8Sources
ClinVar
gnomAD v2.1
gnomAD v4.1
gnomAD-Canada
SpliceAI
OncoKB
COSMIC
Cancer hotspots
Triaged references · 1 PMID not cited in assessment
28492532 ↗ Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. CLINVAR